MetaVia announces presentation of pre-clinical data on DA-1241

MetaVia (MTVA) announced the presentation of pre-clinical data on DA-1241, a novel G-Protein-Coupled Receptor 119 agonist, demonstrating additive hepatoprotective effects in combination with Efruxifermin, a fibroblast growth factor 21 analogue, in a metabolic dysfunction-associated steatohepatitis mouse model. The data will be presented in a poster session, tomorrow, at the American Diabetes Association’s 85th Scientific Sessions, taking place June 20-23, 2025, at the McCormick Place Convention Center in Chicago, Illinois. The pre-clinical study was conducted with mice fed a Gubra Amylin NASH diet for 36 weeks to induce advanced liver pathology consistent with human MASH. Mice were then randomized to receive either vehicle, DA-1241, Efruxifermin, or the combination therapy for 12 weeks.